Navigation Links
Perrigo and its Partner Synthon Launch Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
Date:11/7/2011

ALLEGAN, Mich., Nov. 7, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB's Xyzal® Oral Solution. Synthon has the first to file ANDA application for the generic that entitle it to 180 days of generic exclusivity. Hatch Waxman litigation in this product was settled earlier this year. Perrigo is the manufacturer of this product.

Xyzal® Oral Solution is indicated for the treatment of indoor and outdoor allergies. It is estimated that it has annual sales of approximately $12 million, according to data provided by Wolters, Kluwer.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This is another example of Perrigo's commitment to bring new products to market. Perrigo continues to deliver on its mission to provide quality, affordable healthcare to consumers."

Synthon's CEO Rudy Mareel commented, "Levocetirizine is a prime example of several ANDAs for which Synthon has obtained 'First-Filer'-status with 180 days Hatch-Waxman marketing exclusivity. The successful launch of Levocetirizine oral solution yet again is proof to Synthon's achievements and our fruitful cooperation with Perrigo."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Synthon Pharmaceuticals, Inc., with its U.S. headquarters and laboratories located in Research Triangle Park, North Carolina, markets generic drugs through partnerships with other leading pharmaceutical companies. Synthon currently holds several approved, or tentatively approved, drug applications and has a pipeline containing more than a dozen products that are expected to be filed with the FDA within the next few years. Synthon Pharmaceuticals, Inc. is part of the Synthon group, a global privately held specialty pharma company with offices, laboratories and manufacturing sites in 11 countries worldwide. (www.synthon.com)

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott
2. Perrigo Announces Launch of Generic Version of Elestat®
3. Perrigo Company to Attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology
4. Perrigo Reports Record Quarterly Revenue and Adjusted Earnings and Raises Full Year Adjusted EPS Guidance
5. Perrigo Company Announces Quarterly Dividend
6. Perrigo Expands Infant Formula Distribution in China With Founder Group
7. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
8. Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam
9. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
10. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
11. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced the addition ... their offering. ... This report analyzes the worldwide markets for Endodontic Supplies in US$ ... , Japan , Europe , ... World. Annual estimates and forecasts are provided for the period 2015 ...
(Date:12/8/2016)... de 2016  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela ... para a doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of ... , , ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... , ... "TransPanel Volume 2 is a package of fading panel transitions that ... of Pixel Film Studios. , TransPanel Volume 2 is a set of fading ... versatile transitions features presets with up to 4 panels with complementary line animations. ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... assistance from offices in Pasco and Richland, is initiating a charity drive to ... injuries resulting from a recent automobile collision. , On October 29th of ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing dual ... opening of the Sober College Robert Pfeifer Memorial Learning Center at its location ... was attended by an overwhelming amount of alumni, family, colleagues and friends of ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... "I had ... an inventor from Winchester, Va. "I thought that if the nebulizer had a more ... rather than fearing them." , He developed the patent-pending NEBY to avoid the need ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
Breaking Medicine News(10 mins):